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Nucleoside phosphoesters (nucleotides) have crucial roles in a large variety of biological processes
including nucleic acid biosynthesis and their corresponding analogues are extensively used as
biological tools. Herein, we describe a new and efficient synthetic procedure involving polyethylene
glycol (PEG) as soluble support and regioselective mono-, di-, and triphosphorylation steps. Applied
to natural and synthetic cytosine containing nucleosides, this methodology allowed the preparation
of various phosphorylated forms in high yields and good purity.
Introduction
Nucleotides, especially nucleoside 50-phosphorylated
forms, are involved in many fundamental biological processes
and pathways,1 and constitute an important area of research.
Thus, several procedures have been reported for the conver-
sion of a nucleoside to its corresponding 50-mono-, di-, or
triphosphorylated forms, using classical solution synthesis.2
The phosphorylation success depends considerably on the
nature of the substrate and to date no protocol for making
nucleoside 50-triphosphates is universally satisfactory. More-
over, solution methods usually yield to complex crude mix-
tures which require tedious purification steps involving first
ion-exchange chromatography on DEAE-Sephadex in aqu-
eous buffers. In addition to the desired nucleotides, the crude
mixture also contains large amounts of inorganic salts, such as
inorganic phosphates, thatmaybe eliminated by anadditional
purification step by using preparative C18 reverse-phase
HPLC. Usually, this fastidious and long purification proce-
dure, associated with the relative low chemical stability of
these derivatives, induces a decrease in yields.
Since Merrifield et al.3 introduced the use of polymer-
supported synthesis of oligopeptides, insoluble supports
have become an important tool for organic synthesis,4
especially for the synthesis of biopolymers,5,6 such as oligo-
nucleotides, peptides, and carbohydrates. Few works have
been reported on the supported synthesis of nucleoside
triphosphates,7-18 with the aim of reaching completion of
(1) Williams, D. M.; , Blackburn, G. M., Nucleic acid chemistry and
biology; Royal Society of Chemistry: Letchworth, UK, 2007.
(2) Burgess, K.; Cook, D. Chem. Rev. 2000, 100, 2047–2059.
(3) Merrifield, R. B. J. Am. Chem. Soc. 1963, 85, 2149–2154.
(4) D€orwald, F. Z. Organic synthesis on solid phase; Wiley-VCH:
New York, 2000.
(5) Seeberger, P. H.; Haase, W. C. Chem. Rev. 2000, 100, 4349–4394.
(6) Venkatesan, N.; Kim, B. H. Chem. Rev. 2006, 106, 3712–3761.
(7) Ahmadibeni, Y.; Parang, K. Org. Lett. 2005, 7, 5589–5592.
(8) Ahmadibeni, Y.; Parang, K. Org. Lett. 2005, 7, 1955–1958.
(9) Ahmadibeni, Y.; Parang, K. J. Org. Chem. 2005, 70, 1100–1103.
(10) Ahmadibeni, Y.; Parang, K. J. Org. Chem. 2006, 71, 5837–5839.
(11) Ahmadibeni, Y.; Parang, K. J. Org. Chem. 2006, 71, 6693–6696.
(12) Ahmadibeni, Y.; Parang, K. Org. Lett. 2007, 9, 4483–4486.
(13) Ahmadibeni, Y.; Parang, K. Angew. Chem., Int. Ed. 2007, 46, 4739–
4743.
(14) Bradley, M.; , Bruckler, C. WO 2007/110624 A2, 2007.
(15) Brownlee, G. G.; Fodor, E.; Pritlove, D. C.; Gould, K. G.; Dalluge,
J. J. Nucleic Acids Res. 1995, 23, 2641–2647.
(16) Gaur, R. K.; Sproat, B. S.; Krupp, G. Tetrahedron Lett. 1992, 33,
3301–3304.
(17) Lebedev, A. V.; Koukhareva, T. II; Beck, M. M. V. Nucleosides,
Nucleotides, Nucleic Acids 2001, 20, 1403–1409.
(18) Schoetzau, T.; Holletz, T.; Cech, D. Chem. Commun. 1996, 387–388.
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the reaction (use of excess reagent) and to greatly simplify
purification processes. These works were based on the use of
the phosphoramidite chemistry and among these, only
Parang et al.7-13 have developed a regioselective method
for nucleoside 50-phosphates and 50-thio-phosphates synth-
esis. Thus, the use of a new phosphorylation reagent im-
mobilized on solid support allowed the desired derivatives to
be isolated in good yields (∼80%) and acceptable HPLC
purity (70-90%).
Despite the benefits offered by the solid phase approach,
the heterogeneous reaction conditions (due to the nature of
the insoluble polymers) often induce other problems such as
nonlinear reaction kinetics, unequal distribution and/or
access to the reaction sites, solvation problems, inefficient
coupling rates, and difficulties for intermediates analysis.
The search for alternative methodologies, aiming to restore
homogeneous reaction conditions, has led to the develop-
ment of soluble polymer supports. These last have received
considerable attention because such a “liquid phase” synth-
esis retains many of the conventional solution chemistry
advantages (high reactivity, lack of diffusion, and easy
analysis) while still allowing a smooth isolation and purifica-
tion of the product.19,20
In addition, soluble polymers are usually much less
expensive than insoluble ones. As an example, soluble poly-
ethylene glycol (PEG), polyvinyl alcohol, and other poly-
mers have been successfully used for the synthesis of
bio-oligomers (peptides,21,22 oligonucleotides,23,24 polysac-
charides)25 and small molecules.19 More recently fluorous
phase26-28 and ionic liquids29-35 have also been reported as
useful soluble supports for organic synthesis and olignucleo-
tide preparation.36,37
Among these soluble polymer supports, PEG has been
wildly used for the liquid-phase oligonucleotide synthesis.38
Borona et al.39-47 have developed a high-efficiency liquid
phase (HELP) method for large-scale synthesis of oligonu-
cleotides based on a PEG strategy; to date these works have
not been adapted for nucleotide (nucleoside mono-, di-, and
triphosphates) preparation. Thus, to develop a new nucleo-
tide synthetic approach and to easily transfer the traditional
solution-phase conditions to a supported methodology, we
propose herein a new technology based on the use of a
soluble PEG support.
Results and Discussion
Supported Nucleotide Synthesis: Polyethylene Glycol
(PEG). The wide application of PEG in organic synthesis is
closely related to its broad solubility profile. It is soluble in
N,N-dimethylformamide (DMF), dichloromethane, toluene,
acetonitrile, water, and methanol, but insoluble in diethyl
ether, tert-butyl methyl ether, isopropyl alcohol, and cold
methanol. Therefore, excess reagents and some byproduct
could readily be eliminated at the end of each reaction step
by using a simple precipitation from diethyl ether of the
polymer-substrate followed up by filtration, and even-
tually additional purification by flash chromatography
may be performed. A commercially available PEG of 4000
Da average molecular weight was selected as the starting
material. Analyses of each supported intermediates were
performed by nuclear magnetic resonance spectra (1H, 13C,
and 31P NMR).
Functionalization of PEG andCoupling Step.The synthetic
strategy is based on PEG anchored to the nucleoside
(nucleobase) through a basolabile linker. This procedure
was selected to develop a synthetic method suitable for the
preparation of nucleotide modified on the glycosidic moiety;
indeed such a modification is often encountered within
nucleoside analogues with antiviral and antitumoral proper-
ties. Thus, we focused on the synthesis of nucleotides
containing cytosine as nucleobase namely cytidine (C),
20-deoxycytidine (dC), and cytarabine (araC, 1-β-D-arabino-
furanosylcytosine), a nucleoside analogue commonly used as
an antitumoral agent in the treatment of acute myelogenous
leukemia.48,49 Initial functionalization of PEG support with
the basolabile linker was performed through the coupling of
PEG-(OH)2 with succinic anhydride in the presence of a
catalytic amount of 4-dimethylaminopyridine (DMAP) in
pyridine.45 A quantitative rate of fonctionalization was
estimated by 13C NMR analysis by observing the shifts of
CH2R and CH2β PEG signals (Figure 1).
Then, the anchoring of C, dC, and araC was performed as
follows. Each nucleoside was linked to the PEG-(O-
succinate)2 1 through the exocyclic amino group of the
(19) Gravert, D. J.; Janda, K. D. Chem. Rev. 1997, 97, 489–509.
(20) Toy, P. H.; Janda, K. D. Acc. Chem. Res. 2000, 33, 546–554.
(21) Mutter, M.; Bayer, E. Angew. Chem., Int. Ed. Engl. 1974, 13, 88–89.
(22) Mutter, M.; Hagenmaier, H.; Bayer, E.Angew. Chem., Int. Ed. Engl.
1971, 10, 811–812.
(23) Cramer, F.; Helbig, R.; Hettler, H.; Scheit, K. H.; Seliger, H.Angew.
Chem., Int. Ed. Engl. 1966, 5, 601.
(24) Hayatsu, H.; Khorana, H. G. J. Am. Chem. Soc. 1966, 88, 3182–
3183.
(25) Guthrie, R. D.; Jenkins, A. D.; Stehlice, J J. Chem. Soc. C 1971,
2690–2696.
(26) Curran, D. P.Med. Res. Rev. 1999, 19, 432–438.
(27) Miura, T.; Goto,K. T.; Hosaka,D.; Inazu, T.Angew. Chem., Int. Ed.
2003, 42, 2047–2051.
(28) Mizuno, M.; Goto, K.; Miura, T.; Matsuura, T.; Inazu, T. Tetra-
hedron Lett. 2004, 45, 3425–3428.
(29) Chan, T. H.; Damha, M. J.; Miao, W.; Donga, R. A.; He, X. WO
2006096963, 2006.
(30) Fraga-Dubreuil, J.; Bazureau, J. P.Tetrahedron Lett. 2001, 42, 6097–
6100.
(31) He, X.; Chan, T. H. Org. Lett. 2007, 9, 2681–2684.
(32) Huang, J. Y.; Lei,M.;Wang, Y.G.Tetrahedron Lett. 2006, 47, 3047–
3050.
(33) Miao, W.; Chan, T. H. Acc. Chem. Res. 2006, 39, 897–908.
(34) Miao, W. S.; Chan, T. H. J. Org. Chem. 2005, 70, 3251–3255.
(35) Vaultier, M.; Roche, C.; Gmouh, S.; Commercon, A. WO
2008003836, 2006.
(36) Donga, R. A.; Khaliq-Uz-Zaman, S.M.; Chan, T. H.; Damha,M. J.
J. Org. Chem. 2006, 71, 7907–7910.
(37) Wada, T.; Narita, R.; Kato, Y.; Saigo, K. WO 2005070859, 2005.
(38) Kitamura, A.; Horie, Y.; Uchida, T.; Yoshida, T. US 6380378,
1999.
(39) Bonora, G. M. Appl. Biochem. Biotechnol. 1995, 54, 3–17.
(40) Bonora, G. M.; Biancotto, G.; Maffini, M.; Scremin, C. L. Nucleic
Acids Res. 1993, 21, 1213–1217.
(41) Bonora, G. M.; Ivanova, E.; Zarytova, V.; Burcovich, B.; Veronese,
F. M. Bioconjugate Chem. 1997, 8, 793–797.
(42) Bonora, G. M.; Scremin, C. L.; Colonna, F. P.; Garbesi, A. Nucleic
Acids Res. 1990, 18, 3155–3159.
(43) Bonora, G. M.; Scremin, C. L.; Colonna, F. P.; Garbesi, A. Nucleo-
sides, Nucleotides 1991, 10, 269–273.
(44) Colonna, F. P.; Scremin, C. L.; Bonora, G. M. Tetrahedron Lett.
1991, 32, 3251–3254.
(45) Denapoli, L.; Messere, A.; Montesarchio, D.; Piccialli, G.; Santa-
croce, C.; Bonora, G. M. Nucleosides, Nucleotides 1993, 12, 21–30.
(46) Scremin, C. L.; Bonora, G. M. Tetrahedron Lett. 1993, 34, 4663–
4666.
(47) Zaramella, S.; Bonora,G.M.Nucleosides, Nucleotides 1995, 14, 809–
812.
(48) Jordheim, L. P.; Galmarini, C. M.; Dumontet, C. Bull. Cancer 2005,
92, 239–248.
(49) Talley, R. W.; Vaitkevicius, V. K. Blood 1963, 21, 352–362.
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nucleobase in the presence of 1-hydroxybenzotriazole
(HOBT) andN,N0-dicyclohexylcarbodiimide (DCC) as cou-
pling agents in a mixture of anhydrous dichloromethane and
DMF (Scheme 1).50 This protocol allowed anchoring regio-
selectively the selected nucleoside onto the polymer without
prior protection of the sugar hydroxyl functions. The PEG-
nucleosides 2a, 2b, and 2c were unequivocally characterized
by 1HNMR spectroscopy, which also confirms the complete
removal of reagents (first ascertained by TLC). Coupling
rates were estimated by comparing 1H NMR integration of
both signals of the H6 from the nucleobase and of the
methylene groups of the succinyl linker (Figure 2). Conver-
sions were quantitative and yields were between 83% and
87%. With one nucleoside at each end of the polymeric
chain, the capacity of the synthesized PEG-nucleoside was
evaluated to be 0.5 mmol 3 g
-1.
Monophosphorylation Step. In a preliminary set of ex-
periments, the monophosphorylation reaction was optimized
with araC as nucleosidic model. To prepare nucleoside
SCHEME 1a
aReagents and conditions: (a) succinic anhydride, DMAP, pyridine, rt, 2 days, 86%; (b) DCC, HOBT, CH2Cl2, DMF, 60 C, 6 h; (c) POCl3,
PO(OEt)3/35 C or CH3CN/0 C, 1 h; (d) TEAB 1 M, pH 7.5; (e) NH4OHc, rt, 1 h.
FIGURE 1. Determination of PEG functionalization with succi-
nyl linker by 13C NMR (100 MHz) analysis: (left) starting
PEG-(OH)2
13C NMR spectrum (CDCl3) with δ 61.5 ppm for
CH2R and δ 72.8 ppm for CH2β; (right) PEG-(O-succinate)2 13C
NMR spectrum (CDCl3) with δ 64.2 ppm for CH2R and δ 68.9 ppm
for CH2β.
FIGURE 2. 1H NMR (300 MHz) spectrum of PEG-C (D2O).
(50) Guo, Z. W.; Gallo, J. M. J. Org. Chem. 1999, 64, 8319–8322.
(51) Gouy,M.H.; Fabre,H.; Blanchin,M.D.; Peyrottes, S.; Perigaud, C.;
Lefebvre, I. Anal. Chim. Acta 2006, 566, 178–184.
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50-monophosphates the regioselective method of Yoshikawa
et al.,52,53 previously described for solution synthesis, was
adapted. As conventional monophosphorylation of unpro-
tected nucleosides requires the use of trialkylphosphate as
solvent and phosphorus oxychloride as phosphorylating agent,
an initial attempt was carried out in these conditions. Unfortu-
nately, PEG-araC 2a was soluble at neither 0 C nor room
temperature in triethylphosphate. The solubility of the PEG-
supported nucleoside was only achieved when reaching the
temperature of 35-40 C. As acetonitrile could solubilize the
PEG moiety at 0 C, it was also considered an alterna-
tive solvent. Thus, several experimental conditions (solvent,
temperature, reaction times, and phosphorus oxychloride
equivalents) were screened and selected data are presented in
Table 1. Monophosphorylation conversion ratios were esti-
mated with 1HNMR analysis by comparing integration of the
signals of the H6 or H5 nucleobase protons (Figure 3). Indeed,
the signals of the H6 proton from the nucleoside 5
0-monopho-
sphate differed from that of the nucleoside by 60 Hz (0.2 ppm,
downfield).
These conversion ratios were also confirmed with HPLC
analysis of a sample aliquot after cleavage of the succinyl
linker in between the support and the nucleot(s)ide. In each
case, regioselectivity of the phosphorylation (at the
50-position) was evidenced by the 1H NMR and 31P NMR
spectra. Longer reaction times did not improve the phos-
phorylation rate significantly (entries 5-7) whereas increas-
ing the phosphorus oxychloride amount led to the reaction
completion (entries 2-4 and 5, 8, and 11). Thus, the use of
dry triethylphosphate appeared a better alternative than
acetonitrile (entries 1 and 10). As both solvents were able
to dissolve the substrate (PEG-araC) and the reactant
(POCl3), the effect of the triethylphosphate was attributed
to the formation of a complex54 between the nucleobase and
the 50-hydroxyl function of the nucleoside, and not to
solubility or temperature effects (as previously reported for
solution phase synthesis).52,53 Finally, PEG-araCMP 3awas
obtained by treating PEG-araC 2awith 15 equiv of POCl3 in
PO(OEt)3 at 35-40 C during 1 h. After hydrolysis of the
reaction mixture with TEAB (1M, pH 7.5), remaining salts
were eliminated by a simple and easy extraction process
(dichloromethane-water) and PEG-supported nucleoside
50-monophosphate 3a was isolated in 92% yield, after pre-
cipitation in cold diethyl ether.
Recovery of araCMP (HPLCpurity: 97%)was performed
after cleavage of the succinyl linker, using concentrated
ammonia. A filtration of the crude through a reverse phase
RP18 column was performed to eliminate PEG residue and
succinimide (the byproduct generated from the cleavage of
succinate linker) was removed by dialysis.
A similar procedure was applied to PEG-C 2c and the use
of 30 equiv of POCl3 was required to observe the complete
disappearance of the supported nucleoside.During the PEG-
dCMP 3b synthesis, the 30-hydroxyl function also underwent
phosphorylation at high temperature (30-40 C) and a
mixture of both nucleoside 50- and 30- monophosphates
was obtained. To avoid this lack of regioselectivity the
reaction was performed in acetonitrile at 0 C. At lower
temperature, only the desired nucleoside 50-monophosphate
3b was observed and the use of 30 equiv of POCl3 was
necessary to complete the reaction. Finally, CMPand dCMP
were obtained after ammonia treatment; corresponding
yields and purities are presented in Scheme 1.
TABLE 1. Optimization of Supported araC Monophosphorylation Step
entry equiv ofPOCl3 time (h) solvent/temp (C) % HPLC a araC/araCMP
1 10 6 CH3CN/0 53 47
2 20 3 CH3CN/0 31 69
3 30 3 CH3CN/0 24 76
4 50 3 CH3CN/0 18 82
5 5 1 PO(OEt)3/35-40 57 43
6 5 3 PO(OEt)3/35-40 69 31
7 5 6 PO(OEt)3/35-40 69 31
8 10 1 PO(OEt)3/35-40 15 85
9 10 3 PO(OEt)3/35-40 14 86
10 10 6 PO(OEt)3/35-40 11 89
11 15 1 PO(OEt)3/35-40 3 97
12 15 3 PO(OEt)3/35-40 9 91
13 15 6 PO(OEt)3/35-40 7 93
aDetermined by HPLC51 after cleavage of the linker in between the support and the nucleot(s)ide.
FIGURE 3. Determination of monophosphorylation rate by 1H
NMR analysis: 1H NMR (300 MHz, in D2O) spectrum obtained
after monophosphorylation of PEG-araC in experimental condi-
tions corresponding to entry 1, Table 1.
(52) Yoshikawa, M.; Kato, T. Bull. Chem. Soc. Jpn. 1967, 40, 2849–2853.
(53) Yoshikawa,M.;Kato, T.; Takenish, TTetrahedron Lett. 1967, 5065–
5068.
(54) Ikemoto, T.; Haze, A.; Hatano, H.; Kitamoto, Y.; Ishida, M.; Nara,
K. Chem. Pharm. Bull. 1995, 43, 210–215.
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Di- and Triphosphorylation Steps. The triphosphorylation
procedure was first considered following the Ludwig et al.55
one-pot method, using unprotected nucleoside as starting
material. Consequently, the phosphorodichloridate inter-
mediate was generated with use of the monophosphoryla-
tion conditions previously optimized (PO(OEt)3, 35-40 C,
15 equiv of POCl3, 1 h) and the reaction mixture was
treated by an excess of tri-n-butylammonium pyropho-
sphate (1 M solution in DMF). Unfortunately, hydrolysis
and purification afforded a mixture of the mono- and the
triphosphate-supported nucleosides with a prevalent pro-
portion of PEG-araCMP 3a. As the completion of the
reaction was a key factor for success, another method
described by Hoard et al.,56 which could easily be monitored
by 31P NMR analysis, was investigated. This procedure
required the nucleoside 50-monophosphate activation by
1,1-carbonyldiimidazole (CDI) and then condensation of
the 50-phosphoroimidazolidate intermediate with inorganic
phosphate or pyrophosphate, which led to the desired nu-
cleoside 50-di- or triphosphate derivatives (Scheme 2).
Formationof the imidazolidate fromPEG-araCMP 3a in the
presence of an excess of CDI (6 equiv) was complete after 3 h.
Indeed, the 31P NMR signal corresponding to the supported
nucleoside monophosphate (signal at 0 ppm, Figure 4A) dis-
appeared whereas the concomitant formation of the imidazo-
lidate (signal at-10 ppm, Figure 4B) was observed. Unreacted
CDI was decomposed withmethanol and then a large excess of
organic phosphate was added. As shown in Figure 4C, 31P
NMR signals observed after 24 h confirmed that activated
imidazolidate species (δ-10 ppm) were efficiently converted to
the diphosphate derivative (two peaks corresponding to Pβ at
-9.2 ppm and to PR at -12 ppm). As the precipitation and
extraction processes were not sufficient to eliminate the excess
phosphate salts, purification of the PEG-supported nucleoside
diphosphate 5a was performed by reverse phase C18 column
chromatography. Elution with water removed all remaining
salts and supported substratewas elutedwith amixture ofwater
and acetonitrile (50/50, v/v).
FIGURE 4. 31P NMR (DMSO-d6) spectra of the PEG-araCMP diphosphorylation procedure: (A) starting material PEG-araCMP; (B)
reaction mixture, 3 h after CDI addition; and (C) reaction mixture 24 h after tri-n-butylammonium phosphate addition.
SCHEME 2a
aReagents and conditions: (a) CDI, DMF, rt, 3 h; (b) tri-n-butylammonium phosphate (1M solution in DMF), rt, 24 h; (c) NH4OHc, rt, 1 h; (d) tri-n-
butylammonium pyrophosphate (1 M solution in DMF), rt, 24 h.
(55) Ludwig, J. Acta Biochim. Biophys. Acad. Sci. Hung. 1981, 16, 131–
133.
(56) Hoard, D. E.; Ott, D. G. J. Am. Chem. Soc. 1965, 87, 1785–1788.
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The crude supported product was lyophilized to afford
PEG-araCDP 5a in 66% yield. A similar procedure was
applied for PEG-araCTP 6a synthesis (69%), using tri-n-
butylammoniumpyrophosphate salts insteadof tri-n-butylam-
monium phosphate salts. Then, treatment of 5a and 6a with
concentrated aqueous ammonia yielded araCDP 7a and
araCTP 8a, as ammonium salts, respectively, with 87% and
83%HPLC purity after RP18 purification and dialysis. Start-
ing fromPEG-dCMP 4b, the sameprocedureswere carried out
and afforded either the dCDP 7b or the dCTP 8b (Scheme 2).
When applied to PEG-CMP 3c, these protocols led to the
expected derivatives PEG-CDP 5c and PEG-CTP 6c as well
as two side products (Scheme 3). Themajor contaminantwas
identified as the corresponding 20,30-protected nucleotide
(9 or 10). Formation of these derivatives is due to the
particular reactivity of the cis-diol functionality of ribose-
containing nucleosides in the presence of CDI excess. How-
ever, formation of these derivatives was not puzzling as
concomitant removal of the 20,30-carbonate group was ex-
pected during the final cleavage step with basic conditions.
Structures of minor contaminants 11 and 12 (dioxapho-
spholane derivatives involving a cyclic monophosphate be-
tween the 20 and the 30 positions) were proposed on the basis
of the presence of an extra phosphate signal at δ 19 ppm,
already described in the literature for 20,30-cyclic phosphate
nucleosides.57,58 Furthermore, theHPLC-MS analysis of the
crude mixture after cleavage showed peaks corresponding to
compounds 13 and 14. In the meantime, El Tayeb et al.58
reported that phosphorylation of the 20- and 30-hydroxy
groups may occurred during the triphosphorylation,55 and
this side reaction is associated with the presence of bulky
substituents on the pyrimidine nucleobase. In our case, steric
hindrance of PEGsupport attached onto the nucleobasemay
be involved in the 20,30 phosphorylation process. Indeed,
such a side reaction was not observed when the reaction was
performed in solution from unprotected cytidine 50-mono-
phosphate (cf. CTP solution synthesis).
Thus, after performing the cleavage step CDP 7c or CTP
8c was obtained, albeit contaminated by a small amount of
20,30-cyclic phosphate 13 or 14 (7% and 10%, respectively)
and unfortunately final purification on reverse phase did not
allow the separation of this byproduct.
Comparison between Solution and Supported Nucleotide Syn-
thesis.To compare our novel soluble PEG-supportedmethodo-
logy to the corresponding synthesis in solution (in termsofnum-
berof step, yields, andHPLCpurities,Table 2)wealsoprepared
araCMP, araCDP, and araCTP using traditional methods.
AraCMP was obtained by solution phase synthesis, using
phosphorus oxychloride in PO(OEt)3 as previously reported
byYoshikawa.52,53After cumbersome purification steps (ion
exchange chromatography DEAE-Sephadex, reverse phase
C18 chromatography, and conversion into sodium salt with
Dowex resin) araCMP was recovered in modest to good
yields depending of the reaction scale (70% for 200 mg of
SCHEME 3a
aReagents and conditions: (a) CDI, DMF, rt, 3 h; (b) tri-n-butylammonium phosphate (1 M solution in DMF), rt, 24 h; (c) tri-n-butylammonium
pyrophosphate (1 M solution in DMF), rt, 24 h; (d) EtOH-H2O, NEt3, rt, 3 h; (e) NH4OHc, rt, 1 h.
TABLE 2. Comparison of Solution and Supported Synthesis of Phosphoester Derivatives of araC
solution support
yield (%) HPLC purity (%) no. of steps yielda (%) HPLC purity (%) no. of steps
araCMP, 4a 40-70 98 1 60 97 3
araCDP, 7a 45 84 2 53 87 4
araCTP, 8a 10 85 2 55 83 4
aOverall yield for supported synthesis included coupling, phosphorylation, and cleavage and isolation steps.
(57) Davies,D.B.;Sadikot,H.J.Chem.Soc.,PerkinTrans. 21983, 1251–1258.
(58) El-Tayeb,A.;Qi,A.D.;Muller,C.E. J.Med.Chem.2006, 49, 7076–7087.
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starting material and 40% for 1 g). This result is mainly due
to the numerous purification steps needed to eliminate the
remaining salt on a larger scale. Supported monophosphor-
ylation was also carried out on two different scales (200 mg
and 1 g of supported nucleoside), meanwhile no variation on
the overall yields was observed (60% including coupling of
the nucleoside to the support, monophosphorylation, and
cleavage steps). Solution synthesis of araCDP and araCTP
was also performed following the Hoard et al.56 method
starting from araCMP. For the araCDP synthesis yields on
both support and in solution were similar (∼50%). Remark-
ably, using our supported methodology the yield of the
nucleoside 50-triphosphate synthesis was 5-fold the one
obtained by the solution approach.
One can see thatwealso succeeded in reaching similarHLPC
purities with 50-mono-, di-, and triphosphate nucleoside-sup-
ported synthesis (Table 2), without performing ion-exchange
DEAE-Sephadex purification but only using precipitation/
extraction or precipitation/RP18 filtration processes.
Conclusion
We have set up a new synthetic approach for the supported
synthesis of nucleoside phosphoesters using PEG as a soluble
support. Compared to classical solution procedures, our
methodology is efficient, scalable, and easy to handle. Thus,
cytosine-containing nucleoside 50-mono, di-, and triphosphate
derivatives were prepared in similar higher yields with accep-
table purity. Furthermore, the isolation procedures have been
simplified and led to a reduction in the overall process time.
Experimental Section
General Procedure for PEG-Supported Nucleoside Synthesis.
To a stirred solution of PEG succinate 1 (0.95 mmol, 1 equiv) in
dichloromethane (70 mL) was added a solution of the required
nucleoside (2 equiv) in DMF (30 mL). Then, DCC (3.79 mmol,
4 equiv) and HOBT (1.89 mmol, 2 equiv) were added and the
resulting mixture was stirred at 60 C for 7 h. The solvents were
evaporated under reduced pressure; the residue was dissolved in a
minimum of dichloromethane and left overnight at 4 C. The
dicyclohexyl urea was filtered off, and the filtrate was concentrated
under reduced pressure and dissolved in DMF (40 mL). The
resulting solution was slowly added to an excess volume of cold
diethyl ether (400mL).Theprecipitatewas filteredandwashedwith
diethyl ether. The final product was recrystallized from absolute
ethanol (40 mL) and dried under vacuum over KOH pellets.
Poly(ethylene glycol)4000 bis[4-N-(1-(β-D-arabinofuranosyl)-
cytosyl)succinate] 2a: Coupling between PEG succinate 1
(4 g, 0.95 mmol) and araC (0.46 g, 1.89 mmol) was performed
with the general procedure and afforded compound 2a as a
white solid (3.65 g, 83%). Rf (CH2Cl2/MeOH, 7/3, v/v) 0.7; δH
(200MHz;D2O) 8.16 (d, J6-5=7.5Hz, 1H,H6), 7.26 (d, J5-6=
7.5 Hz, 1H, H5), 6.10 (d, J10-20 = 4.6 Hz, 1H, H10), 4.34 (pt, J=
4.6Hz, 1H, H20), 4.16 (m, 2H, (OCH2R)PEG), 4.02-3.92 (m, 2H,
H30 H40), 3.73 (m, 2H, H50a H50b), 3.70-3.33 (m, (OCH2)PEG),
2.76-2.62 (m, 4H, CH2succ); δC (75MHz;D2O) 174.6, 174.5 (2s,
CdOsucc), 162.5 (s, C4), 156.7 (s, C2), 146.7 (s, C6), 97.3 (s, C5),
87.1 (s, C10), 84.0 (s, C40), 75.4 (s, C20), 75.2 (s, C30), 69.6 (s,
(OCH2)PEG), 68.4 (s, (OCH2β)PEG), 64.1 (s, (OCH2R)PEG), 60.7
(s, C50), 31.5, 28.5 (2s, CH2succ).
General Procedure for the Monophosphorylation of Polymer-
Supported Nucleoside.A solution of PEG-supported nucleoside
(1 equiv) in triethylphosphate (10 mL/mmol) was warmed to
40 C. Phosphorus oxychloride (15 equiv) was added and the
mixture was stirred for 1 h at 40 C. Excess of reagent was
hydrolyzed by addition of an aqueous triethylammonium bi-
carbonate buffer solution (1M, pH 7) and the resulting mixture
was concentrated under reduced pressure. The residue was
dissolved in dichloromethane and the organic layer was washed
with water. The aqueous layer was extracted several times
by dichloromethane. The organic layers were combined and
evaporated under reduced pressure. The supported nucleoside
50-monophosphate was precipitated from a dichloromethane
solution by addition of an excess volume of cold diethyl ether.
The precipitatewas filtered, washedwith diethyl ether, anddried
under vacuum over KOH.
Poly(ethylene glycol)4000 bis[4-N-(1-(5
0-O-monophosphoryl-β-
D-arabinofuranosyl)cytosyl)succinate], triethylammonium salt
3a: Monophosphorylation of PEG-araC 2a (3 g, 0.64 mmol)
was performed with the general procedure and afforded com-
pound 3a as awhite solid (2.99 g, 92%). δH (300MHz;D2O) 8.34
(d, J6-5= 7.5Hz, 1H,H6), 7.10 (d, J5-6= 7.5Hz, 1H,H5), 6.18
(d, J10-20 = 5.0 Hz, 1H, H10), 4.42 (m, 1H, H20), 4.19 (m, 2H,
(OCH2R)PEG), 4.10-4.15 (m, 4H, H30 H40 H50a H50b), 3.30-3.90
(m, (OCH2)PEG), 3.10 (q, J = 7.3 Hz, 6H, (CH3CH2)3NH),
2.62-2.85 (m, 4H, CH2succ), 1.18 (t, J = 7.3 Hz, 9H, (CH3-
CH2)3NH); δC (100 MHz; D2O) 174.7, 174.4 (2s, CdOsucc),
159.0 (s, C4), 148.1 (s, C2), 145.2 (s, C6), 96.9 (s, C5), 87.0 (s, C10),
82.3 (d, JC40-P = 8.0 Hz, C40), 75.8 (s, C20), 74.1 (s, C30), 69.6 (s,
(OCH2)PEG), 68.4 (s, (OCH2β)PEG), 64.1 (s, OCH2R)PEG), 63.6
(s, C50), 46.6 (s, (CH3CH2)3NH), 31.6, 28.3 (2s, CH2succ), 8.2 (s,
(CH3CH2)3NH); δP (121 MHz; D2O) 0.26 (s).
General Procedure for the Diphosphorylation of Polymer-
Supported Nucleoside. A suspension of PEG-supported nucleo-
side 50-monophosphate (1 equiv) in tributylamine (10 mmol,
100 equiv) was stirred for 10 min at room temperature. Cold
diethyl ether was added and the precipitate was filtered, washed
with diethyl ether, anddried overnight under vacuumoverKOH
pellets. Then, the supported nucleoside 50-monophosphate was
dissolved in anhydrous DMF (10 mL/mmol) and CDI (6 equiv)
was added. The reaction mixture was stirred for 2 h at room
temperature and treated with anhydrous methanol (24 equiv) to
hydrolyze the excess of CDI. After 15 min, a solution of
tributylammonium phosphate (1 M solution in anhydrous
DMF, 15 equiv) was added and the suspension was stirred for
24 h at room temperature. The mixture was treated with an
equal volume of methanol and then concentrated under reduced
pressure. The residue was precipitated with cold diethyl ether;
the precipitate was filtered and washed with diethyl ether.
Purification of the crude material was performed on reverse
phase column (linear gradient fromwater to 70% acetonitrile in
water).
Poly(ethylene glycol)4000 bis[4-N-(1-(5
0-O-diphosphoryl-β-D-
arabinofuranosyl)cytosyl)succinate], tributylammonium salt 5a:
Diphosphorylation of PEG-araCMP 3a (0.50 g, 0.09 mmol)
was performed with the general procedure and afforded com-
pound 5a as a white solid (0.36 g, 66%) after freeze-drying. δH
(300MHz;D2O) 8.24 (d, J6-5=7.5Hz, 1H,H6), 7.27 (d, J5-6=
7.5 Hz, 1H, H5), 6.17 (d, J10-2’ = 5.1 Hz, 1H, H10), 4.42 (pt, J=
5.1 Hz, 1H, H20), 4.28-4.05 (m, 6H, H30 H40 H50a H50b
(OCH2R)PEG), 3.89-3.35 (m, (OCH2)PEG), 2.92 (t, J =
7.7 Hz, 12H, (CH3CH2CH2CH2)3NH), 2.80-2.68 (m, 4H,
CH2succ), 1.54 (m, 12H, (CH3CH2CH2CH2)3NH), 1.29
(m, 12H, (CH3CH2CH2CH2)3NH), 0.81 (t, J = 7.2 Hz, 18H,
(CH3CH2CH2CH2)3NH); δC (100 MHz; D2O) 174.6, 174.4 (2s,
CdOsucc), 162.5 (s, C4), 156.8 (s, C2), 146.8 (s, C6), 97.6 (s, C5), 86.6
(s, C10), 82.0 (d, JC40-P=9.0Hz, C40), 75.1 (s, C20), 74.3 (s, C30), 69.6
(s, (OCH2)PEG), 68.4 (s, (OCH2β)PEG), 64.1 (s, (OCH2R)PEG), 64.1
(s, C50), 52.6 (s, (CH3CH2CH2CH2)3NH), 31.6, 28.4 (2s, CH2succ),
25.2 (s, (CH3CH2CH2CH2)3NH), 19.2 (s,CH3CH2CH2CH2)3NH-
), 12.8 (s, (CH3CH2CH2CH2)3NH); δP (121 MHz, D2O) -10.44
(m, Pβ),-11.03 (m, PR).
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General Procedure for the Triphosphorylation of Polymer-
Supported Nucleoside 50-Monophosphate. A suspension of
PEG-supported nucleoside 50-monophosphate (1 equiv) in tribu-
tylamine (10 mmol, 100 equiv) was stirred for 10 min at room
temperature. Then, cold diethyl ether was added and the precipi-
tate was filtered, washed, and dried overnight under vacuum over
KOH pellets. The resulting supported nucleoside 50-monopho-
sphate was dissolved in anhydrousDMF (10mL/mmol) and CDI
(6 equiv) was added. The anhydrous reaction mixture was stirred
for 2 h at room temperature and treatedwith anhydrousmethanol
(24 equiv) to hydrolyze the CDI excess. After 15min, a solution of
tributylammonium pyrophosphate (1 M solution in anhydrous
DMF, 15 equiv) was added. The suspensionwas stirred for 24 h at
room temperature. Themixture was treated with an equal volume
of methanol and then concentrated under reduced pressure. The
residue was precipitated with cold diethyl ether. The precipitate
was filtered and washed with diethyl ether. Column chromatog-
raphyof the crudematerialwasperformedon reversephase (linear
gradient from water to 70% acetonitrile in water).
Poly(ethylene glycol)4000 bis[4-N-(1-(5
0-O-triphosphoryl-β-D-
arabinofuranosyl)cytosyl)succinate], tributylammonium salt 6a:
Triphosphorylation of PEG-araCMP 3a (0.50 g, 0.09 mmol)
was performed with the general procedure and afforded com-
pound 6a as a white solid (0.43 g, 69%) after freeze-drying.
δH (300 MHz; D2O) 8.29 (d, J6-5 = 7.5 Hz, 1H, H6), 7.17 (d,
J5-6 = 7.5 Hz, 1H, H5), 6.17 (d, J10-2’ = 5.1 Hz, 1H, H10), 4.41
(pt, J = 5.1 Hz, 1H, H20), 4.27-4.05 (m, 6H, H30 H40 H50a H50b
(OCH2R)PEG), 3.88-3.30 (m, (OCH2)PEG), 3.03 (t, J=7.4 Hz,
18H, (CH3CH2CH2CH2)3NH), 2.87-2.65 (m, 4H, CH2succ),
1.57 (m, 18H, (CH3CH2CH2CH2)3NH), 1.27 (m, 18H, (CH3-
CH2CH2CH2)3NH), 0.83 (t, J = 7.1 Hz, 27H, (CH3CH2CH2-
CH2)3NH); δC (100 MHz; D2O) 174.7, 174.5 (2s, CdOsucc),
161.5 (s, C4), 155.1 (s, C2), 147.6 (s, C6), 97.2 (s, C5), 86.6 (s, C10),
82.0 (d, JC40-P = 9.0 Hz, C40), 75.2 (s, C20), 74.0 (s, C30), 69.6 (s,
(OCH2)PEG), 68.4 (s, (OCH2β)PEG), 64.2 (s, (OCH2R)PEG), 64.1
(d, JC50-P = 8.0 Hz, C50), 52.6 (s, (CH3CH2CH2CH2)3NH),
31.6, 28.4 (2s, CH2succ), 25.2 (s, (CH3CH2CH2CH2)3NH),
18.3 (s, CH3CH2CH2CH2)3NH), 12.8 (s, (CH3CH2CH2-
CH2)3NH); δP (121 MHz, D2O) -10.94 (d, Jγ-β=19.4 Hz,
Pγ), -11.32 (d, JR-β = 19.4 Hz, PR), -23.28 (t, Jβ-γ=Jβ-R =
19.4 Hz, Pβ).
General Procedure for the Cleavage of Supported Substrates
and Nucleotides Recovery. PEG-supported nucleotide (0.05
mmol, 1 equiv) was dissolved in concentrated ammonia (2 mL).
The solution was stirred at room temperature for 1 h and then
evaporatedunder reducedpressure. Purificationwasperformedon
reverse phase column (elution with water) and dialysis.
1-(β-D-Arabinofuranosyl)cytosine-50-monophosphate, ammonium
salt 4a: The general procedure was applied to PEG-araCMP
3a (0.15 g, 0.02 mmol) and led to a mixture (15 mg) of araCMP
and succinamide (ratio: 93/7). The succinamide was elimi-
nated by dialysis in water (2 mL) overnight and araCMP 4a
(13 mg, 68%) was recovered as a white solid after freeze-drying.
λmax(H2O)/272 nm (ε/dm
3 mol-1 cm-1 7100), 247 (4100);
δH (300 MHz; D2O) 7.88 (d, J6-5=7.6 Hz, 1H, H6), 6.11 (d,
J10-20 =5.3Hz, 1H,H10), 6.02 (d, J5-6=7.6Hz, 1H,H5), 4.34 (pt,
J=5.3Hz 1H,H20), 4.11-3.96 (m, 4H,H30 H40 H50aH50b); δC (100
MHz; D2O) 161.2 (s, C4), 151.0 (s, C2), 144.4 (s, C6), 94.7 (s, C5),
85.5 (s, C10), 81.5 (d, JC40-P=9.0Hz, C40), 75.3 (s, C20), 73.5 (s, C30),
63.1 (d, JC50-P= 4.0Hz, C50); δP (121MHz, D2O) 0.45 (s); LC/MS
(ESI) m/z 322 (M - NH4þ).
1-(β-D-Arabinofuranosyl)cytosine-50-diphosphate, ammonium
salt 7a: The general procedure was applied to PEG-araCDP
5a (0.34 g, 0.05 mmol) and led to a mixture (55 mg) of araCDP
and succinamide (ratio: 88/12). An aliquot (10 mg) was dis-
solved in water (2 mL) and submitted to dialysis. AraCDP 7a
(8.50mg, 96%)was obtained as awhite solid after freeze-drying.
λmax(H2O)/274 nm (ε/dm
3 mol-1 cm-1 7900), 246 (3800);
δH (300 MHz; D2O) 7.85 (d, J6-5=7.6 Hz, 1H, H6), 6.14 (d,
J10-20 = 5.4 Hz, 1H, H10), 6.03 (d, J5-6=7.6 Hz, 1H, H5), 4.35
(pt, J=5.4Hz, 1H, H20), 4.20-4.10 (m, 3H, H30 H50a H50b), 4.00
(m, 1H, H40); δC (100 MHz; D2O) 166.1 (s, C4), 157.4 (s, C2),
142.7 (s, C6), 95.7 (s, C5), 85.1 (s, C10), 81.1 (d, JC40-P = 9.0 Hz,
C40), 75.3 (s, C20), 73.6 (s, C30), 63.6 (d, JC50-P = 5.0 Hz, C50); δP
(121 MHz, D2O) -10.42 (d, Jβ-R = 20.6 Hz, Pβ), -11.10
(d, JR-β = 20.6 Hz, PR); LC/MS (ESI) m/z 402 (M þ H -
2NH4
þ).
1-(β-D-Arabinofuranosyl)cytosine-50-triphosphate, ammonium
salt 8a: The general procedure was applied to PEG-araCTP 6a
(0.43 g, 0.07 mmol) and led to a mixture (68 mg) of araCTP and
succinamide (ratio: 95/5). An aliquot (8.5 mg) was dissolved in
water (2 mL) and submitted to dialysis. AraCTP 8a (8 mg, 92%)
was obtained as awhite solid after freeze-drying. λmax(H2O)/273
nm (ε/dm3 mol-1 cm-1 8700), 246 (4500); δH (300 MHz; D2O)
7.85 (d, J6-5=7.6Hz, 1H,H6), 6.14 (d, J10-20 =5.4Hz, 1H,H10),
6.04 (d, J5-6 = 7.6 Hz, 1H, H5), 4.35 (pt, J= 5.4 Hz, 1H, H20),
4.20-4.12 (m, 3H, H30 H50a H50b), 4.01 (m, 1H, H40); δC (100
MHz; D2O) 166.0 (s, C4), 157.3 (s, C2), 142.8 (s, C6), 95.7 (s, C5),
85.3 (s, C10), 81.1 (d, JC40-P = 9.0 Hz, C40), 75.4 (s, C20),
73.6 (s, C30), 64.0 (d, JC50-P = 5.0 Hz, C50); δP (121 MHz, D2O)
-10.45 (d, Jγ-β=18.2Hz, Pγ),-11.20 (d, JR-β=19.4Hz, PR),
-22.96 (t, Jβ-γ = Jβ-R = 18.2 Hz, Pβ); LC/MS (ESI) m/z 482
(M þ 2H - 3NH4þ).
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